文献速递白血病造血干细胞移植与细胞治疗

高危AML脐血移植后GVHD预防:日本全国队列研究

GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.
PubMed 文献 · Blood Adv · 2026-01-01

该研究纳入2010至2023年间日本3222例首次接受脐血移植的高危急性髓系白血病成人患者,比较钙调磷酸酶抑制剂联合霉酚酸酯或甲氨蝶呤的GVHD预防方案。霉酚酸酯方案中性粒细胞植入更快,但急性和慢性GVHD发生率更高,2年总生存和无病生存甲氨蝶呤更优,霉酚酸酯还增加人疱疹病毒6型脑炎风险。

要点

  • 霉酚酸酯方案中性粒细胞植入快于甲氨蝶呤方案(P < .001)。
  • 霉酚酸酯方案2至4级急性GVHD和慢性GVHD发生率均更高(P < .001)。
  • 甲氨蝶呤方案2年总生存和无病生存更高(P < .001和P = .003)。

核心结论

  • 两种方案均支持高危AML成功进行脐血移植,但甲氨蝶呤方案有适度生存优势。
  • 霉酚酸酯加速植入的获益被更高的GVHD和病毒感染并发症所抵消。

研究设计与样本

  • 日本全国性回顾性队列研究,纳入2010至2023年首次接受脐血移植的3222例高危AML成人患者。
  • GVHD预防方案为环孢素或他克莫司联合霉酚酸酯或甲氨蝶呤。

主要发现

  • 霉酚酸酯方案中性粒细胞植入快于甲氨蝶呤方案(P < .001)。
  • 霉酚酸酯方案2至4级急性GVHD(P < .001)和慢性GVHD(P < .001)发生率显著更高。
  • 2年移植相关死亡率为26%至38%,复发率为41%至46%。
  • 甲氨蝶呤方案2年总生存(P < .001)和无病生存(P = .003)更高。
  • 霉酚酸酯使用与人疱疹病毒6型脑炎风险增加相关。

关键数值与推荐

  • 多变量分析显示 adverse prognostic factors 包括年龄≥55岁、男性、Karnofsky体能状态<80、造血干细胞移植特异性合并症指数较高、移植时未缓解。

临床怎么用

  • 高危AML脐血移植后GVHD预防需根据患者和移植特征个体化选择。
  • 选择霉酚酸酯方案时需权衡快速植入与GVHD及病毒并发症风险。

局限性

  • 回顾性研究设计。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cord blood transplantation (CBT) is a curative option for patients with high-risk acute myeloid leukemia (AML), including therapy-related AML (t-AML). However, the optimal prophylaxis for graft-versus-host disease (GVHD) remains unclear. We conducted a nationwide, retrospective cohort study including 3222 adults with high-risk AML (t-AML and non-t-AML) who underwent their first CBT in Japan between 2010 and 2023. GVHD prophylaxis consisted of cyclosporine or tacrolimus combined with mycophenolate mofetil (CSP/TAC + MMF) or methotrexate (CSP/TAC + MTX). MMF regimens were associated with faster neutrophil engraftment than MTX regimens (P < .001). However, CSP/TAC + MMF showed significantly higher incidences of grades 2 to 4 acute GVHD (P < .001) and chronic GVHD (P < .001). Two-year transplant-related mortality and relapse rates were 26 to 38% and 41 to 46%, respectively. Overall survival and disease-free survival at 2 years were higher with MTX than with MMF (P < .001 and P = .003, respectively), indicating a modest survival advantage for MTX. Multivariable analysis identified older age (≥55 years), male sex, Karnofsky performance status <80, higher hematopoietic cell transplantation-specific comorbidity index, and no remission at transplantation as adverse prognostic factors. Notably, MMF use was associated with an increased risk of human herpesvirus 6 encephalitis. Both CSP/TAC + MMF and CSP/TAC + MTX regimens support successful CBT in high-risk AML. Although MMF accelerates engraftment, this benefit is offset by greater GVHD and viral complications. These real-world, nationwide data highlight the need to individualize GVHD prophylaxis based on patient and transplant characteristics and provide essential benchmarks for future multicenter prospective studies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Yamasaki S, Yanada M, Mizuno S, et al. GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study. Blood Adv. 2026. PMID: 41538306. doi:10.1182/bloodadvances.2025018626

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。